Gotowa bibliografia na temat „Dyscrasite”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Dyscrasite”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Dyscrasite"
Osadchii, E., D. Boström, S. Lunin i E. Rosén. "Thermodynamic properties of dyscrasite (Ag 3 Sb) at isostatic pressures 4000-8000 bar". Physics and Chemistry of Minerals 25, nr 4 (19.03.1998): 288–91. http://dx.doi.org/10.1007/s002690050116.
Pełny tekst źródłaKalinin, Arkadii A., Yevgeny E. Savchenko i Ekaterina A. Selivanova. "Mustard Gold in the Oleninskoe Gold Deposit, Kolmozero–Voronya Greenstone Belt, Kola Peninsula, Russia". Minerals 9, nr 12 (13.12.2019): 786. http://dx.doi.org/10.3390/min9120786.
Pełny tekst źródłaZachariáš, Jiří, i Matěj Němec. "Gold to aurostibite transformation and formation of Au-Ag-Sb phases: the Krásná Hora deposit, Czech Republic". Mineralogical Magazine 81, nr 4 (sierpień 2017): 987–99. http://dx.doi.org/10.1180/minmag.2016.080.145.
Pełny tekst źródłaHartshorn, Edward A., Gary M. Levin i C. Lindsay DeVane. "A Review of Cyclic Antidepressant-Induced Blood Dyscrasias". Annals of Pharmacotherapy 26, nr 3 (marzec 1992): 378–83. http://dx.doi.org/10.1177/106002809202600313.
Pełny tekst źródłaLatif, Zahid, Faraz Jabbar i Brendan D. Kelly. "Clozapine and blood dyscrasia". Psychiatrist 35, nr 1 (styczeń 2011): 27–29. http://dx.doi.org/10.1192/pb.bp.109.026054.
Pełny tekst źródłaSutherland, Rory A., i Richard I. Crawford. "Scalp biopsy identifies systemic amyloidosis presenting as isolated telogen effluvium: A case report". SAGE Open Medical Case Reports 7 (styczeń 2019): 2050313X1984778. http://dx.doi.org/10.1177/2050313x19847783.
Pełny tekst źródłaDunk, Louisa R., Linda J. Annan i Christopher D. Andrews. "Rechallenge with clozapine following leucopenia or neutropenia during previous therapy". British Journal of Psychiatry 188, nr 3 (marzec 2006): 255–63. http://dx.doi.org/10.1192/bjp.188.3.255.
Pełny tekst źródłaHarris, Donald C., Andrew C. Roberts, J. H. Gilles Laflamme i Chris J. Stanley. "Criddleite, TlAg2Au3Sb10S10, a New Gold-Bearing Mineral from Hemlo, Ontario, Canada". Mineralogical Magazine 52, nr 368 (grudzień 1988): 691–97. http://dx.doi.org/10.1180/minmag.1988.052.368.13.
Pełny tekst źródłaMunshi, Tariq, Farooq Naeem, Mohammed Ayub, Saeed Farooq, Davit Khachatryan, Selim Asmer, Peter Wang i in. "The haematological side effects of clozapine: literature review and meta-analysis". BJPsych Open 7, S1 (czerwiec 2021): S274. http://dx.doi.org/10.1192/bjo.2021.729.
Pełny tekst źródłaMichaeli, J., R. Niesvizky, D. Siegel, M. Ladanyi, PH Lieberman i DA Filippa. "Proteinaceous (angiocentric sclerosing) lymphadenopathy: a polyclonal systemic, nonamyloid deposition disorder". Blood 86, nr 3 (1.08.1995): 1159–62. http://dx.doi.org/10.1182/blood.v86.3.1159.1159.
Pełny tekst źródłaRozprawy doktorskie na temat "Dyscrasite"
Ali, H. S. "Drug induced blood dyscrasias : Aminoglutethimide and related compounds". Thesis, Cardiff University, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.377874.
Pełny tekst źródłaLimpas, Yvon. "Le POEMS syndrome : entité particulière au sein des dyscrasies plasmocytaires". Bordeaux 2, 1989. http://www.theses.fr/1989BOR25325.
Pełny tekst źródłaPaletta, Dominique Raoux. "Syndrome de Crow-Fukase : à propos d'une observation et revue de la littérature". Montpellier 1, 1988. http://www.theses.fr/1988MON11235.
Pełny tekst źródłaSoubrier, Martin. "Le Syndrome POEMS". Clermont-Ferrand 1, 2003. http://www.theses.fr/2003CLF1MM11.
Pełny tekst źródłaGutknecht-Dignat, Sandrine. "Le syndrome d'hyperperméabilité capillaire idiopathique : à propos d'un cas". Montpellier 1, 1998. http://www.theses.fr/1998MON11040.
Pełny tekst źródłaCARLISI, Melania. "EVALUATION AND POTENTIAL ROLE OF BONE MARROW TISSUE-RESIDENT MEMORY T-CELLS IN PATIENTS WITH PLASMA CELL DYSCRASIAS". Doctoral thesis, Università degli Studi di Palermo, 2020. http://hdl.handle.net/10447/400371.
Pełny tekst źródłaMILANI, PAOLO. "The use of mass spectrometry for the diagnosis of plasma cell dyscrasias: focus on light chain (AL) amyloidosis patterns". Doctoral thesis, Università degli studi di Pavia, 2019. http://hdl.handle.net/11571/1285988.
Pełny tekst źródłaKiran, Aramanda Shanmukha. "Exotic eutectic microstructures". Thesis, 2021. https://etd.iisc.ac.in/handle/2005/5476.
Pełny tekst źródłaHavyarimana, Sandra. "Evaluation of prognostic markers in plasma cell dyscrasias". Thesis, 2017. https://hdl.handle.net/10539/24917.
Pełny tekst źródłaIntroduction: Plasma cell dyscrasias (PCDs) are a heterogeneous group of diseases in which there is expansion of clonal plasma cells which may produce monoclonal immunoglobulins. CD200 is a membrane glycoprotein of the type I immunoglobulin superfamily transmembrane glycoprotein. It is postulated that CD200 is expressed by the plasma cells in a significant number of cases of multiple myeloma (MM), but normal plasma cells do not express it. It may thus assist in confirming clonality of plasma cells in PCDs. Aims: To evaluate CD200 expression as a potential diagnostic and prognostic marker in plasma cell dyscrasias and to compare the results with other known prognostic factors. Methods: CD200 expression was evaluated by immunophenotypic analysis on normal, reactive and clonal plasma cells and expressed as a mean fluorescent intensity (MFI) value. Cut-off for positive CD200 was established. A negative population was established using different methodologies to exclude reactive plasma cells. CD200 was then compared with diagnostic and prognostic markers currently in use in our laboratory. Results: An MFI of ≥ 30 was the cut-off for CD200 positivity. CD200 was expressed by 76.5% of PCDs cases. CD200 did not predict anaemia, hypercalcaemia or renal dysfuction which are biochemical criteria for the diagnosis of multiple myeloma. CD200 expression did not correlate with traditional prognostic markers such as beta 2 microglobulin (β2M), lactate dehydrogenase (LDH) or genetic abnormalities (by fluorescence in situ hybridization analysis). Cases with plasma cell CD200 expression had a higher monoclonal band level compared to those without CD200 expression. Conclusion: CD200 is a useful tool to evaluate plasma cell clonality; however in our settings where there is a high prevalence of infectious diseases, particularly HIV infection, CD200 might yield false positive results most likely because of small oligoclones of reactive plasma cells. CD200 as a prognostic tool in PCDs could not be confirmed in this small study.
LG2018
Phipps, Jonathan E. "Toward Personalized Medicine: The potential role of RNA interference in Plasma Cell Dyscrasia". 2011. http://trace.tennessee.edu/utk_graddiss/1217.
Pełny tekst źródłaKsiążki na temat "Dyscrasite"
Roccaro, Aldo M., i Irene M. Ghobrial, red. Plasma Cell Dyscrasias. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5.
Pełny tekst źródłaKelly, John J., Robert A. Kyle i Norman Latov. Polyneuropathies Associated with Plasma Cell Dyscrasias. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2065-4.
Pełny tekst źródłaMinetti, Luigi, Giuseppe D’Amico i Claudio Ponticelli, red. The Kidney in Plasma Cell Dyscrasias. Dordrecht: Springer Netherlands, 1988. http://dx.doi.org/10.1007/978-94-009-1315-8.
Pełny tekst źródła1928-, Kyle Robert A., i Latov Norman, red. Polyneuropathies associated with plasma cell dyscrasias. Boston: Nijhoff, 1987.
Znajdź pełny tekst źródłaL, Minetti, D'Amico G. 1929- i Ponticelli C, red. The Kidney in plasma cell dyscrasias. Dordrecht: Kluwer Academic Publishers, 1988.
Znajdź pełny tekst źródłaZimmerman, Todd M., i Shaji K. Kumar, red. Biology and Management of Unusual Plasma Cell Dyscrasias. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-6848-7.
Pełny tekst źródłaW, Pruzanski, i Keystone E. C, red. Paraproteins in disease: Investigation of plasma cell dyscrasia. Edinburgh: Churchill Livingstone, 1985.
Znajdź pełny tekst źródłaW, Pruzanski, i Keystone E. C, red. Paraproteins in desease: Investigation of plasma cell dyscrasia. Edinburgh: Churchill Livingstone, 1985.
Znajdź pełny tekst źródłaGhobrial, Irene M., i Aldo M. Roccaro. Plasma Cell Dyscrasias. Springer, 2018.
Znajdź pełny tekst źródłaPlasma Cell Dyscrasias. Springer, 2016.
Znajdź pełny tekst źródłaCzęści książek na temat "Dyscrasite"
Castroviejo, Ricardo. "Dyscrasite (dy, dyscrasite, stibiotriargentite)". W A Practical Guide to Ore Microscopy—Volume 1, 265–68. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-12654-3_44.
Pełny tekst źródłaSpeer, Tod W., Christin A. Knowlton, Michelle Kolton Mackay, Charlie Ma, Lu Wang, Larry C. Daugherty, Brandon J. Fisher i in. "Dyscrasias". W Encyclopedia of Radiation Oncology, 168. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-85516-3_596.
Pełny tekst źródłaMateos, María-Victoria, i Ola Landgren. "MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology". W Plasma Cell Dyscrasias, 3–12. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_1.
Pełny tekst źródłaNeri, Paola, Nizar J. Bahlis, Claudia Paba-Prada i Paul Richardson. "Treatment of Relapsed/Refractory Multiple Myeloma". W Plasma Cell Dyscrasias, 169–94. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_10.
Pełny tekst źródłaLonial, Sagar. "Treatment of MM: Upcoming Novel Therapies". W Plasma Cell Dyscrasias, 195–205. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_11.
Pełny tekst źródłaLee, Susan J., i Ivan Borrello. "Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma". W Plasma Cell Dyscrasias, 207–25. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_12.
Pełny tekst źródłaJethava, Yogesh S., i Frits van Rhee. "Transplantation for Multiple Myeloma". W Plasma Cell Dyscrasias, 227–50. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_13.
Pełny tekst źródłaEda, Homare, Loredana Santo, G. David Roodman i Noopur Raje. "Bone Disease in Multiple Myeloma". W Plasma Cell Dyscrasias, 251–70. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_14.
Pełny tekst źródłaDispenzieri, Angela, i Giampaolo Merlini. "Immunoglobulin Light Chain Systemic Amyloidosis". W Plasma Cell Dyscrasias, 273–318. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_15.
Pełny tekst źródłaKapoor, Prashant, Stephen M. Ansell i Esteban Braggio. "Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment". W Plasma Cell Dyscrasias, 321–61. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40320-5_16.
Pełny tekst źródła